An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Study Shows BDI Screening of Existing Patient CT Scans for Undetected Osteoporosis Also Finds Undetected Cardiovascular Disease Risk Many studies have shown the inverse relationship between bone mineral density (BMD) – the gold standard measure for osteopenia/osteoporosis – and coronary calcium...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * New Study Shows that Ozempic® Reduces the Risk of Heart Attack, Stroke, and Death by 23% Compared to Dulaglutide On September 18, Novo Nordisk announced results from the REACH real-world study, which demonstrated that compared to dulaglutide, Ozempic® (once-weekly injectable semaglutide) was...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves MiniMed 780g System for Adults with Type 2 Diabetes On September 2, Medtronic announced two U.S. Food and Drug Administration (FDA) regulatory milestones that broaden the MiniMed™ 780G system portfolio: clearance of the SmartGuard™ algorithm as an interoperable automated...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves Wegovy (semaglutide) to Treat MASH On August 15, the U.S. Food and Drug Administration has approved Wegovy (semaglutide) injection to treat metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis (excessive scar tissue in the liver). MASH, also known as nonalcoholic steatohepatitis,...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Positive Phase 3 Trial Results for Lilly’s Oral Weight-Loss Drug, Orforglipron On August 7, Eli Lilly and Company announced positive topline results from the Phase 3 ATTAIN-1 trial, evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, in 3,127 adults...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves SKYTROFA® for the Once-Weekly Treatment of Adults with GHD On July 28, Ascendis Pharma A/S announced that the U.S. Food & Drug Administration (FDA) has approved SKYTROFA® (lonapegsomatropin-tcgd; developed as TransCon hGH) for the replacement of endogenous growth hormone in adults with...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Recordati Rare Diseases Announced New Data in Cushing’s Syndrome, Cushing’s Disease, and Post-Bariatric Hypoglycaemia at ENDO 2025 In April 2025, the FDA approved an expanded indication for ISTURISA® (osilodrostat) for the treatment of endogenous hypercortisolemia in adults with Cushing’s syndrome Recordati Rare...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Results from AMGEN’S Phase 2 Obesity Study OF Monthly MariTide Presented at The American Diabetes Association 85th Scientific Sessions MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau,...
